scholarly journals Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry

2017 ◽  
Vol 20 (1) ◽  
pp. 100-110 ◽  
Author(s):  
Marco Canepa ◽  
Ewa Straburzynska-Migaj ◽  
Jaroslaw Drozdz ◽  
Carla Fernandez-Vivancos ◽  
Jose Manuel Garcia Pinilla ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
European Society ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Heart Failure Patients ◽  
European Society Of Cardiology

scholarly journals Cardiopulmonary syndrome and adrenoreactivity of an organism

2016 ◽  
Vol 97 (6) ◽  
pp. 864-869 ◽  
Author(s):  
V M Gazizyanova ◽  
O V Bulashova ◽  
A A Nasybullina ◽  
Z A Shaykhutdinova ◽  
A A Podol’skaya
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Features ◽  
Clinical Manifestations ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Heart Failure Patients ◽  
Increased Activity

Aim. To study β-adrenoreactivity of the cell membrane in patients with different variants of heart failure in association with chronic obstructive pulmonary disease.Methods. 120 heart failure patients including 68 of them who suffer from concominant chronic obstructive pulmonary disease were evaluated. Assessment of clinical features of heart failure, patients’ quality of life and study of β-adrenoreactivity were performed.Results. Adrenoreactivity of an organism in heart failure and concominant chronic obstructive pulmonary disease was 2 times higher and was 55.4±18.8 U and in heart failure only it was 29.4±8.5 U. Intensification of β-adrenoreactivity was found to be proportional to worsening of clinical features of chronic heart failure in all patients that was more prominent in patients with pulmonary disease. Responders with heart failure in association with chronic obstructive pulmonary disease had higher values of β-adrenoreactivity of cell membranes more frequently.Conclusion. The results of our investigation confirm increased activity of sympathetic system in heart failure and concominant chronic obstructive pulmonary disease that worsens clinical manifestations of heart failure.

Impact of abnormal body water distribution on prognostic of Chronic Obstructive Pulmonary Disease and heart failure patients

2020 ◽  
Author(s):  
Manuel Abraham Gómez Martínez ◽  
Arturo Orea Tejeda ◽  
Dulce González Islas ◽  
María Elena Quintero Martínez ◽  
Valeria Ariadna Martínez Vázquez ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Water Distribution ◽  
Body Water ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Heart Failure Patients

scholarly journals Characteristics of Beta-blocker Treatment in Cardiac Patients with Concomitant Chronic Obstructive Pulmonary Disease

2016 ◽  
Vol 1 (3) ◽  
pp. 276-279
Author(s):  
Attila Frigy ◽  
Katalin Mezei ◽  
Ildikó Kocsis ◽  
Lehel Máthé
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Dilated Cardiomyopathy ◽  
Pulmonary Disease ◽  
Beta Blocker ◽  
Scientific Data ◽  
Cardiac Patients ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Heart Failure Patients

Abstract Background: Recent scientific data demonstrated a potential beneficial effect of beta-blocker (BB) therapy in cardiac patients with chronic obstructive pulmonary disease (COPD). Our aim was to characterize the use of beta-blockers in these patients, in “real-life” conditions. Material and methods: We collected retrospectively the data of 60 consecutive cardiac patients (51 men, 9 women, mean age 67 years) with the concomitant diagnosis of COPD: main cardiac conditions, presence and reason of BB therapy, type of drug and dosage, main ECG and echocardiographic parameters, medication and data regarding COPD. Besides descriptive statistics, we compared the data of patients with and without BB therapy (chi-square test, level of significance alpha <0.05) in order to identify factors associated with BB usage. Results: In our study population, 41.6% of the patients had received BB treatment, the most frequently used drug being bisoprolol 2.5 mg and 5 mg q.d. (28%-28%), followed by carvedilol (32%). The prevalence of BB therapy was 51.2% in heart failure patients (48% in NYHA class III and IV, and 66.6% in dilated cardiomyopathy), 38.4% in hypertension, 81.8% in ischemic artery disease, and 64.7% in subjects with atrial fibrillation. The usage of BB therapy was significantly associated with the presence of heart failure (p = 0.047), dilated cardiomyopathy (p = 0.034), ischemic heart disease (p = 0.005), previous myocardial infarction (p = 0.003) and, inversely, with the acute exacerbation of COPD (p = 0.006). Conclusions: Despite the fact that every cardiac patient with COPD had a potential indication for BB treatment, this was used insufficiently, especially in case of heart failure patients. In daily practice, there is a need for continuous review and improvement of BB usage in these patients.

Sign in / Sign up

Export Citation Format

Share Document